Hjem
Bergithe Eikeland Oftedals bilde

Bergithe Eikeland Oftedal

Forsker
  • E-postbergithe.oftedal@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Jeg er utdannet molekylærbiolog og jobber innen immunogenetikk med fokus på endokrin autoimmun sykdom. Siden disputasen min i 2012 ved Universitetet i Bergen fortsatte jeg som post-Doc i samme gruppe og hadde ett års forskningsopphold hos Professor Hamish Scott ved University of Adelaide hvor jeg jobbet med genetikk. Jeg ble så tildelt et mobilitetsstipend fra Norges Forskningsråd og jobbet to år i gruppen til Professor Georg Holländer ved University of Oxford hvor jeg arbeidet med karakterisering av utvikling av T-celler i tymus. Siden 2019 har jeg vært ansatt som seniorforsker ved KG Jebsen-senteret for autoimmune sykdommer, og jeg ble nylig tildelt det prestisjetunge Excellence Emerging Investigator-stipendet fra Novo Nordic-stiftelsen. Mitt langsiktige mål er å karakterisere genetiske og molekylære mekanismer i det adaptive immunsystemet som er avgjørende for utviklingen av tolerante T-celler og B-celler. Videre vil jeg kombinerer denne kunnskapen i multivariante sykdomsmodeller for bedre å forutsi autoimmunt vevsdestruksjon. I tillegg ønsker jeg å utvide mitt internasjonale nettverk med mulighet for langsiktige samarbeid.

2024 (upcoming): 

Invited speaker at the 21st Biennial Meeting of the European Society for Immunodeficiencies (ESID), Marseille, France, 16.-19. October, 2024

 

2022: 

Invited speaker at European Congress of Endocrinology (ECE) 2022, 21–24 May 2022 in Milan Italy,

Invited speaer at the 20th Biennial Meeting of the European Society for Immunodeficiencies (ESID), Gothenburg, Sweden, 12-15 October, 2022.

2016:    

Invited speaker, 12th Annual Symposium on Primary Immunodeficiency Diseases, California, USA

Selected speaker at the 43rd Scandinavian Society for Immunology meeting, Turku, Finland.

       

2015

Selected speaker at The Thymus Meeting 2015, Venice, Italy

Invited speaker at the Norwegian Immunological Society annual meeting

Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. iScience.
  • Vis forfatter(e) (2024). Regulatory T cells in autoimmune primary adrenal insufficiency. Clinical and Experimental Immunology. 47-57.
  • Vis forfatter(e) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 sider.
  • Vis forfatter(e) (2023). Th17 Cells: Orchestrators of Mucosal Inflammation and Potential Therapeutic Targets. Critical Reviews in Immunology. 25-52.
  • Vis forfatter(e) (2023). Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1. FEBS Letters. 1261-1274.
  • Vis forfatter(e) (2023). Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes. iScience. 17 sider.
  • Vis forfatter(e) (2023). Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. Diabetes. 59-70.
  • Vis forfatter(e) (2023). A partial form of AIRE deficiency underlies a mild form of autoimmune polyendocrine syndrome type 1. Journal of Clinical Investigation.
  • Vis forfatter(e) (2022). Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies. Journal of Autoimmunity. 1-?.
  • Vis forfatter(e) (2022). Extrathymic expression of Aire controls the induction of effective T<inf>H</inf>17 cell-mediated immune response to Candida albicans. Nature Immunology. 1098-1108.
  • Vis forfatter(e) (2021). Transcriptional changes in regulatory T cells from patients with autoimmune polyendocrine syndrome type 1 suggest functional impairment of lipid metabolism and gut homing. Frontiers in Immunology. 1-12.
  • Vis forfatter(e) (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology (EJE). 607-615.
  • Vis forfatter(e) (2021). The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function. Communications Biology.
  • Vis forfatter(e) (2021). Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. Journal of Experimental Medicine (JEM).
  • Vis forfatter(e) (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. 1-14.
  • Vis forfatter(e) (2019). Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
  • Vis forfatter(e) (2019). Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
  • Vis forfatter(e) (2018). Oral microbiota in autoimmune polyendocrine syndrome type 1. Journal of Oral Microbiology. 1-10.
  • Vis forfatter(e) (2018). 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I. Clinical and Experimental Immunology. 1-5.
  • Vis forfatter(e) (2017). T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ. Journal of Autoimmunity. 24-33.
  • Vis forfatter(e) (2017). Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I. Autoimmunity. 211-222.
  • Vis forfatter(e) (2017). Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. Journal of Pediatric Endocrinology & Metabolism (JPEM). 3546-3556.
  • Vis forfatter(e) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
  • Vis forfatter(e) (2016). Antibodies against NALP5 and it's role in hypoparathyroidism in autoimmune polyglandular syndrome type 1. Problemy Endokrinologii. 25-30.
  • Vis forfatter(e) (2016). A variant in the BACH2 gene is associated with susceptibility to autoimmune addison's disease in humans. Journal of Clinical Endocrinology and Metabolism (JCEM). 3865-3869.
  • Vis forfatter(e) (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). 2975-2983.
  • Vis forfatter(e) (2015). Revealing missing human protein isoforms based on Ab initio prediction, RNA-seq and proteomics. Scientific Reports.
  • Vis forfatter(e) (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
  • Vis forfatter(e) (2015). 8q13.1-q13.2 deletion associated with inferior cerebellar vermian hypoplasia and digital anomalies: A new syndrome? Pediatric Neurology. 230-234.e1.
  • Vis forfatter(e) (2014). Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. Journal of Immunology. 3880-3890.
  • Vis forfatter(e) (2014). ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism (JCEM). E1784-E1792.
  • Vis forfatter(e) (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 220-227.
  • Vis forfatter(e) (2013). Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. Journal of Clinical Immunology. 1341-1348.
  • Vis forfatter(e) (2012). Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. Journal of Clinical Immunology. 230-237.
  • Vis forfatter(e) (2011). Measuring autoantibodies against IL-17F and IL-22 in Autoimmune Polyendocrine Syndrome Type I by radioligand binding assay using fusion proteins. Scandinavian Journal of Immunology. 327-333.
  • Vis forfatter(e) (2010). Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 459-467.
  • Vis forfatter(e) (2008). Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
  • Vis forfatter(e) (2008). AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 130-136.
  • Vis forfatter(e) (2005). Ligand-dependent protein interactions of the estrogen receptors using the yeast two-hybrid system. Annals of the New York Academy of Sciences. 420-425.
Mastergradsoppgave
  • Vis forfatter(e) (2005). Exploring protein-protein interactions between ligand activated transcription factors using the yeast two-hybrid system.
Doktorgradsavhandling
  • Vis forfatter(e) (2019). Exploring and redefining Autoimmune polyendocrine syndrome type 1.
  • Vis forfatter(e) (2012). Autoimmune polyendocrine syndrome type I –novel diagnostic assays and immune regulation.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2019). The Natural History of APS1. 7 sider.
  • Vis forfatter(e) (2019). Aire Mutations and Autoimmune Diseases. 24 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Dominant Inheritance in Autoimmune Endocrine Syndrome Type 1. Scandinavian Journal of Immunology. 306-307.
  • Vis forfatter(e) (2012). Deviant expression of defensins in sera and saliva of patients with autoimmune polyendocrine syndrome type I. Immunology. 211-212.
  • Vis forfatter(e) (2010). Nucleoporin 62, a Novel Autoantigen in Patients with Autoimmune Polyendocrine Syndrome Type I (APS I). Scandinavian Journal of Immunology. 493-494.
Poster
  • Vis forfatter(e) (2013). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with APS-1.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2023). Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives. Frontiers in Endocrinology.
  • Vis forfatter(e) (2021). B cells and autoantibodies in aire deficiency. Biomedicines. 1-15.
  • Vis forfatter(e) (2020). The prospects of single-cell analysis in autoimmunity. Scandinavian Journal of Immunology. 1-15.
  • Vis forfatter(e) (2020). New ERA of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology. 1-23.
  • Vis forfatter(e) (2016). AIRE-mutations and autoimmune disease. Current Opinion in Immunology. 8-15.

Se fullstendig oversikt over publikasjoner i CRIStin.

Utvalgte publikasjoner:

2023:

 

36. A partial form of AIRE deficiency underlies a mild form of Autoimmune Polyendocrine Syndrome Type 1.

Oftedal BE, Berger AH, Bruserud Ø, Goldfarb Y, Sulen A, Breivik L, Hellesen A, Ben-Dor S, Haffner-Krausz R , Knappskog PM, Johansson S, Wolff ASB, Bratland E, Abramson J, Husebye ES.

J Clin Invest. 2023 Nov 1;133(21):e169704. doi: 10.1172/JCI169704.

 

35. Regulatory T cells in autoimmune primary adrenal insufficiency.

Sjøgren T, Bjune JI, Husebye ES, Oftedal BE, Wolff ASB.

Clin Exp Immunol. 2023 Aug 14: uxad087. doi: 10.1093/cei/uxad087. Online ahead of print.

 

34. Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies.

Wolff ASB, Hansen L, Grytaas MA, Oftedal BE, Breivik L, Zhou F, Hufthammer KO, Sjøgren T, Olofsson JS, Trieu MC, Meager A, Jørgensen AP, Lima K, Greve-Isdahl Mohn K, Langeland N, Cox RJ, Husebye ES.

iScience. 2023 Jul 21;26(7):107084. doi: 10.1016/j.isci.2023.107084. Epub 2023 Jun 9.

 

33. Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes.

Oftedal BE, Assing K, Baris S, Safgren SL, Johansen IS, Jakobsen MA, Babovic-Vuksanovic D, Agre K, Klee EW, Majcic E, Ferré EMN, Schmitt MM, DiMaggio T, Rosen LB, Rahman MO, Chrysis D, Giannakopoulos A, Garcia MT, González-Granado LI, Stanley K, Galant-Swafford J, Suwannarat P, Meyts I, Lionakis MS, Husebye ES.

iScience. 2023 May 5;26(6):106818. doi: 10.1016/j.isci.2023.106818. eCollection 2023 Jun 16.

 

32. Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1.

Oftedal BE, Delaleu N, Dolan D, Meager A, Husebye ES, Wolff ASB.

FEBS Lett. 2023 Apr 13. doi: 10.1002/1873-3468.14625. Online ahead of print. PMID: 37052889

 

31. Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.

Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL.

Diabetes. 2023 Jan 1;72(1):59-70. doi: 10.2337/db21-1172.PMID: 35709010

 

 

2022:

30. Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies.

Sjøgren T, Bratland E, Røyrvik EC, Grytaas MA, Benneche A, Knappskog PM, Kämpe O, Oftedal BE, Husebye ES, Wolff ASB.

J Autoimmun. 2022 Dec;133:102917. doi: 10.1016/j.jaut.2022.102917. Epub 2022 Sep 30. PMID: 36191466

 

29. Extrathymic expression of Aire modulates the induction of effective TH17 cell-mediated immune response to Candida albicans.

J Dobeš, O Ben-Nun, A Binyamin, L Stoler-Barak, BE Oftedal, Y Goldfarb, N Kadouri, Y Gruper, T Givony, I Zalayat, K Kováčová, H Böhmová, E Valter, Z Shulman, D Filipp, ES Husebye,  J Abramson

Nat Immunol. 2022 Jul;23(7):1098-1108. doi: 10.1038/s41590-022-01247-6. Epub 2022 Jun 27.

PMID: 35761088

 

2021:

28. Transcriptional Changes in Regulatory T Cells from Patients With Autoimmune Polyendocrine Syndrome Type 1 Suggest Functional Impairment of Lipid Metabolism and Gut Homing.

Berger AH, Bratland E, Sjøgren T, Heimli M, Tyssedal T, Bruserud Ø, Johansson S, Husebye ES, Oftedal BE, Wolff ASB.

Front Immunol. 2021 Aug 30;12:722860. doi: 10.3389/fimmu.2021.722860. eCollection 2021.

 

27. Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation

Y. Goldfarb, T. Givony, N. Kadouri, J. Dobeš, C. Peligero-Cruz, I. Zalayat, G. Damari, B. Dassa, S. Ben-Dor, Y. Gruper, BE. Oftedal, E. Bratland, MM. Erichsen, A. Berger, A. Avin, S. Nevo, U. Haljasorg, Y. Kuperman, A. Ulman, R. Haffner-Krausz, Z. Porat, U. Atasoy, D. Leshkowitz, ES. Husebye, J. Abramson

J Exp Med. 2021 Nov 1;218(11):e20201076. doi: 10.1084/jem.20201076. Epub 2021 Sep 3.

 

26. The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function

BE Oftedal, S Maio, A Händel, MPJ White, D Howie, S Davis, N Prevot, IA Rota, ME Deadman, BM Kessler, R Fischer, NS Trede, E Sezgin, RM Maizels, GA Holländer

Nature Communications Biology, Commun. Biol 4, 681 (2021). https://doi.org/10.1038/s42003-021-02203-0

 

25. The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease

ASB Wolff, L Breivik, KO Hufthammer, MA Grytaas, E Bratland, ES Husebye, and BE Oftedal

The European Journal of Endocrinology, DOI: https://doi.org/10.1530/EJE-20-1268, Volume/Issue: Volume 184: Issue 4, Page Range: 607–615

 

24. GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.

D Eriksson, EC Røyrvik, M Aranda-Guillén, AH Berger, N Landegren, HA Alvarez, Å Hallgren, M Grytaas, S Ström, E Bratland, I Botusan, BE Oftedal ,…, S Johansson, O Kämpe, ES Husebye.

Nat Commun. 2021 Feb 11;12(1):959. doi: 10.1038/s41467-021-21015-8.

 

2019

23. Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease.

Aslaksen S, Methlie P, Vigeland MD, Jøssang DE, Wolff AB, Sheng Y, Oftedal BE, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

Front Endocrinol (Lausanne). 2019 Sep 27;10:648. doi: 10.3389/fendo.2019.00648.

 

22. Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease.

Aslaksen S, Wolff AB, Vigeland MD, Breivik L, Sheng Y, Oftedal BE, Artaza H, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

J Transl Autoimmun. 2019 May 28;1:100005. doi: 10.1016/j.jtauto.2019.100005.

 

2018

21. 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I.

Berglund A, Cleemann L, Oftedal BE, Holm K, Husebye ES, Gravholt CH.

Clin Exp Immunol. 2018 Oct 29. doi: 10.1111/cei.13231. PMID: 30372540

 

20.Oral microbiota in autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Siddiqui H, Marthinussen MC, Chen T, Jonsson R, Oftedal BE, Olsen I, Husebye ES, Wolff AB.

J Oral Microbiol. 2018 Feb 26;10(1):1442986. doi: 10.1080/20002297.2018.1442986. PMID: 29503707

 

2017

19. Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune

Polyendocrine Syndrome Type 1.

Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff ASB.

Front Immunol. 2017 Sep 1;8:1074. doi: 10.3389/fimmu.2017.01074. eCollection 2017.

PMID: 28919897

 

18. Salivary gland dysfunction in patients with autoimmune polyendocrine syndrome type I

BE Oftedal, M Cuida, MM Erichsen, M Tveiterås, A Østre, D Hammenfors, M Johnsson, K Kisand, R Klein, R Jonsson, ASB Wolff.

Autoimmunity. 2017 Jun;50(4):211-222. doi: 10.1080/08916934.2017.1344972. Epub 2017 Jul 7.

PMID: 28686485

 

17. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type-1.

EM Orlova, LS Sozaeva, MA Kareva, BE Oftedal, ASB Wolff, L Breivik, EY Zakharova, O Kämpe, PM Knappskog, VA Peterkova, ES Husebye. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3546-3556. doi: 10.1210/jc.2017-00139. PMID: 28911151

 

16. T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ

Oftedal, B.E., Lundgren, B.A., Hamm, D., Finstermeier, K., Gan, P.Y., Holdsworth, S.R., Hahn, C.N., Schreiber, A.W., and Scott, H.S.

J Autoimmun. 2017 Mar 15. pii: S0896-8411(16)30344-4. doi: 10.1016/j.jaut.2017.03.002. [Epub ahead of print]. PMID: 28318808

 

2016

15. A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans

Pazderska A, Oftedal BE, Napier CM, Ainsworth HF, Husebye ES, Cordell HJ, Pearce SH, Mitchell AL.

J Clin Endocrinol Metab. 2016 Nov;101(11):3865-3869. Epub 2016 Sep 28. PMID: 27680876

 

14. A longitudinal follow-up of Autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Oftedal BE, Landegren N, Erichsen M, Bratland E, Lima K, Jørgensen AP, Myhre AG, Svartberg J, Fougner KJ, Bakke Å, Nedrebø BG, Mella B, Breivik L, Viken MK, Knappskog PM, Marthinussen MC, Løvås K, Kämpe O, Wolff AB, Husebye ES.

J Clin Endocrinol Metab. 2016 Jun 2:jc20161821. [Epub ahead of print] PMID: 27253668

 

13. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases

BE Oftedal, A Hellesen, MM Erichsen, E Bratland, A Vardi, J Perheentupa, EH Kemp, T Fiskerstrand, MK Viken, AP Weetman, SJ Fleishman, S Banka, WG Newman, WAC Sewell, LS Sozaeva, T Zayats, K Haugarvoll, EM Orlova, J Haavik, S Johansson, PM Knappskog, K Løvås, ASB Wolff, J Abramson, Eystein S. Husebye

Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021. PMID: 26084028

Impact factor: 24.1

 

2015

12. Revealing Missing Human Protein Isoforms Based on Ab Initio Prediction, RNA-seq and Proteomics

Hu, Z.-Q., Scott, H.S., Qin, G.-G., Zheng, G.-Y., Chu, X., Xie, L., Adelson, D.L., Oftedal, B.E.,

Venugopal, P., Babic, M., Hahn, C.N., Bing Zhang, B., Wang, X.-J., Nan Li, N., and Wei, C.-C.

SCIENTIFIC REPORTS 2015 Volume: 5, Article Number: 10940

 

11. 8q13.1-q13.2 Deletion Associated With Inferior Cerebellar Vermian Hypoplasia and Digital Anomalies: A New Syndrome?

Mordaunt D, Oftedal BE, Scott HS, Coates D, Barnett C

Pediatr Neurol. 2015 Feb;52(2):230-4.e1. doi: 10.1016/j.pediatrneurol.2014.09.002. PMID: 25693585

 

2014

10. Clinical and Serologic Parallels to APS-I in Patients with Thymomas and Autoantigen

Transcripts in Their Tumors.

Wolff ASB, Kärner J,Owe JF, Oftedal BE, Gilhus NE. Erichsen MM, Kämpe E,‖ Meager A, Peterson

P, Kisand K, Willcox N, Husebye ES

J Immunol. 2014 Oct 15;193(8):3880-90. doi: 10.4049/jimmunol.1401068. PMID: 25230752

 

9. ARMC5 MUTATIONS ARE COMMON IN FAMILIAL BILATERAL MACRONODULAR ADRENAL

HYPERPLASIA.

Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal BE, Cutfield R,

Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB, Torpy DJ, Scott HS.

J Clin Endocrinol Metab. 2014 Jun 6:jc20141265. PMID:24905064

Citations: 36 (webofknowledge.com)

 

8. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1.

Breivik L, Oftedal BE, Bøe Wolff AS, Bratland E, Orlova EM, Husebye ES.

Clin Immunol. 2014 Jul;153(1):220-7. doi: 10.1016/j.clim.2014.04.013. Epub 2014 May 2.

 

2013

7. Anti-Cytokine Autoantibodies Preceding Onset of Autoimmune Polyendocrine Syndrome Type I Features in Early Childhood.

Wolff AS, Sarkadi AK, Maródi L, Kärner J, Orlova E, Oftedal BE, Kisand K, Oláh E, Meloni A, Myhre

AG, Husebye ES, Motaghedi R, Perheentupa J, Peterson P, Willcox N, Meager A.

J Clin Immunol. 2013 Oct 26. [Epub ahead of print

 

2011

6. Radioligand-Binding Assay Reveals Distinct Autoantibody Preferences for Type I Interferons in APS I and Myasthenia Gravis Subgroups.

Hapnes L, Willcox N, Oftedal BE, Owe JF, Gilhus NE, Meager A, Husebye ES, Wolff AS.

J Clin Immunol. 2011 Nov 30. [Epub ahead of print] PMID: 22127461

 

5. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyendocrine syndrome type I by radioligand binding assay using fusion proteins.

Oftedal BE, Kämpe O, Meager A, Ahlgren KM, Lobell A, Husebye ES, Wolff AS.

Scand J Immunol. 2011 Apr 28. [Epub ahead of print] PMID:21535082

 

2010

4. Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in

autoimmune polyendocrine syndrome type I.

Wolff AS, Oftedal BE, Kisand K, Ersvaer E, Lima K, Husebye ES.

Scand J Immunol. 2010 Jun;71(6):459-67. PMID: 20500699

Citations: 24 (webofknowledge.com)

 

2008

3. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune

polyendocrine syndrome type I.

Oftedal BE, Wolff AS, Bratland E, Kämpe O, Perheentupa J, Myhre AG, Meager A, Purushothaman R, Ten S, Husebye ES.

Clin Immunol. 2008 Oct;129(1):163-9. Epub 2008 Aug 16.PMID: 18708298

 

2. AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene

deletions contribute to APS I.

Bøe Wolff AS, Oftedal B, Johansson S, Bruland O, Løvås K, Meager A, Pedersen C, Husebye ES,

Knappskog PM.

Genes Immun. 2008 Mar;9(2):130-6. Epub 2008 Jan 17.PMID: 18200029

 

2022-2027           “21-Hydroxylase reactive B cells and their immunotherapeutic potential in autoimmune Addison’s disease”. Funded by the Novo Nordic Fundation. 10 000 000 DKK. Oftedal is the project leader.

2021-2024           “Will B-cell tell the tales? Autoimmune B cells in autoimmune Addison’s disease”. Funded by the Regional Health Authorities. 3 000 000 NOK, Oftedal is the project leader.

2017-2021          “KG Jebsen center for autoimmune disorders”. A national centre established in Bergen, where Oftedal is a principal investigator. Funded by KG Jebsen, 18 000 000.

2017-2020          “Identification of novel monogenic autoimmune syndromes”. Partners are Husebye, Bratland and Wolff. Funded by Norwegian Research Council, 4 000 000 NOK.

2016-2019          “New perspectives on regulation of peripheral tissue antigen expression within the thymus”. Oftedal is the project leader. Partners are Georg Holländer and Eystein Husebye. Funded by the Norwegian Research Council. 3 328 000 NOK

 

Normal 0 false false false EN-GB X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;}